Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;235(9):6230-6245.
doi: 10.1002/jcp.29552. Epub 2020 Feb 3.

Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer

Gamze Guney Eskiler  1 , Gulsah Cecener  2 , Unal Egeli  2 , Berrin Tunca  2
Affiliations

Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer

Gamze Guney Eskiler et al. J Cell Physiol. 2020 Sep.

Abstract

Herein, we investigated efflux pumps-mediated talazoparib-resistance in the treatment of triple-negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib-solid lipid nanoparticles (SLNs) and then explored in vitro therapeutic efficacy of talazoparib-SLNs to overcome talazoparib-resistance in TNBC cells. Talazoparib-SLNs formulation was produced and then characterized. Calcein and Rho-123 were used to analyze the functional activity of drug efflux pumps in these cells. Additionally, RT-PCR, western blot and immunofluorescence analysis were used to detect the messenger RNA, and protein expression level, and cellular localization of the multidrug resistance (MDR1), breast cancer resistance protein (BCRP), and MRP1. We found that talazoparib efflux was mediated by BCRP and MRP1 pumps in TNBC cells. Talazoparib-SLNs could significantly enhance therapeutic efficacy of talazoparib. Furthermore, talazoparib-SLNs were more effective in the suppression of MDR1, BCRP, and MRP1 gene and protein expression levels than talazoparib. Consequently, this study suggests that talazoparib-SLNs formulation represents a promising therapeutic carrier to reverse MDR-mediated resistance in TNBC.

Keywords: multidrug resistance (MDR); nanoparticles; solid lipid nanoparticles (SLNs); talazoparib; triple negative breast cancer (TNBC).

PubMed Disclaimer

References

REFERENCES

    1. Arnason, T., & Harkness, T. (2015). Development, maintenance, and reversal of multiple drug resistance: At the crossroads of TFPI1, ABC transporters, and HIF1. Cancers, 7(4), 2063-2082. https://doi.org/10.3390/cancers7040877
    1. Ashworth, A. (2008). A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology, 26(22), 3785-3790.
    1. Austin Doyle, L., & Ross, D. D. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 22(47), 7340-7358. https://doi.org/10.1038/sj.onc.1206938
    1. Bao, L., Hazari, S., Mehra, S., Kaushal, D., Moroz, K., & Dash, S. (2012). Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. American Journal of Pathology, 180(6), 2490-2503. https://doi.org/10.1016/j.ajpath.2012.02.024
    1. de Bono, J. S. (2013). First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. In ASCO (p. Abstract No: 2580). https://doi.org/10.1200/jco.2013.31.15_suppl.2580

Publication types

MeSH terms